EMERYVILLE, Calif., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Amyris, Inc. (Nasdaq:AMRS), the industrial bioscience company
has executed definitive agreements for its strategic partnership and financing with a global nutraceuticals market leader as
previously described on September 30, 2016. These agreements include the expansion of a new nutraceutical market that is expected
to represent $40-$50 million of annual revenue once developed and scaled, a related strategic investment, and an unsecured credit
facility of $25 million with a five-year maturity.
“We are very pleased with the significant traction we are experiencing in the first market we launched with this partner earlier
this year and the speed by which we’ve been able to execute the expanded agreement into our second nutraceutical market with this
partner. We expect the second nutraceutical product to reach full scale production in 2019 and combined with our first product with
this partner we expect will generate approximately $100 million annually,” said John Melo, Amyris President & CEO. “We expect 2017
revenue from the first targeted product of around $40 million.”
Continued Melo, “We are very pleased with how well our partnership business model is delivering and the strategic nature of our
partners.”
The closing of the collaboration expansion and credit agreements remains subject to obtaining certain required approvals.
About Amyris
Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth.
Amyris applies its innovative bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty
ingredients and consumer products. The company is delivering its No Compromise® products across a number of markets, including
specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, and pharmaceuticals and nutraceuticals. More
information about the company is available at www.amyris.com.
Forward-Looking Statements
This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed
to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events
(such as the expected annual revenue from the collaboration expansion once developed and scaled, the anticipated closing of the
collaboration expansion and credit facility, the expected timeline to reach full scale production for the product under the
collaboration expansion, and the anticipated annual revenue from all products under the partnership as well as from the first
targeted product with the partner) that involve risks and uncertainties. These statements are based on management's current
expectations and actual results and future events may differ materially due to risks and uncertainties, including risks related to
manufacturing capacity at Amyris’s Brotas facility, delays or failures in development, production and commercialization of
products, liquidity and ability to fund capital expenditures, Amyris’s reliance on third parties to achieve its goals, and other
risks detailed in the “Risk Factors” section of Amyris’s quarterly report on Form 10-Q filed on August 9, 2016. Amyris disclaims
any obligation to update information contained in these forward-looking statements whether as a result of new information, future
events, or otherwise.
Amyris, the Amyris logo and Biofene are registered trademarks of Amyris, Inc.
Note to Editors: Please see news release issued September 30, 2016, entitled “Amyris Expands in Global Nutraceuticals Market
with New Collaboration and Partner Funding of $30 Million.”
Contact: Peter DeNardo Director, Investor Relations and Corporate Communications Amyris, Inc. +1 (510) 740-7481 investor@amyris.com pr@amyris.com